Teva Pharmaceutical TEVA announced that it has entered into a strategic collaboration agreement with China-based Fosun ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, and Noetik, a leader in AI-driven spatial and multimodal biology, today announced a research collaboration to develop predictive ...

Phase 2 study, led by Dr. Antonio Jimeno at the University of Colorado Anschutz Medical Campus will evaluate NT219 in ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

Teva collaboration agreement aims to accelerate clinical data generation for TEV-56278 and develop Anti-PD1-IL2 Therapy.

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanomaFosun Pharma-Teva collaboration agreement established with g ...

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, ...

Rahway: Merck, known as MSD outside of the United States and Canada, has announced that the U.S. Food and Drug Administration ...